677 related articles for article (PubMed ID: 28575896)
1. Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis.
Sathiyamoorthy G; Sehgal S; Ashton RW
South Med J; 2017 Jun; 110(6):393-398. PubMed ID: 28575896
[TBL] [Abstract][Full Text] [Related]
2. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.
Hagmeyer L; Treml M; Priegnitz C; Randerath WJ
Respiration; 2016; 91(4):327-32. PubMed ID: 27073887
[TBL] [Abstract][Full Text] [Related]
3. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions.
Raghu G; Selman M
Am J Respir Crit Care Med; 2015 Feb; 191(3):252-4. PubMed ID: 25635489
[No Abstract] [Full Text] [Related]
4. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.
Galli JA; Pandya A; Vega-Olivo M; Dass C; Zhao H; Criner GJ
Respirology; 2017 Aug; 22(6):1171-1178. PubMed ID: 28317233
[TBL] [Abstract][Full Text] [Related]
5. Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?
Hayton C; Chaudhuri N
Drugs Aging; 2017 Sep; 34(9):647-653. PubMed ID: 28861727
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targets in idiopathic pulmonary fibrosis.
Kolb M; Bonella F; Wollin L
Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
[TBL] [Abstract][Full Text] [Related]
7. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
Karimi-Shah BA; Chowdhury BA
N Engl J Med; 2015 Mar; 372(13):1189-91. PubMed ID: 25806913
[No Abstract] [Full Text] [Related]
8. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
[TBL] [Abstract][Full Text] [Related]
9. Developments in the management of idiopathic pulmonary fibrosis.
Drug Ther Bull; 2015 Jul; 53(7):78-81. PubMed ID: 26159700
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series.
Delanote I; Wuyts WA; Yserbyt J; Verbeken EK; Verleden GM; Vos R
BMC Pulm Med; 2016 Nov; 16(1):156. PubMed ID: 27863518
[TBL] [Abstract][Full Text] [Related]
11. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
George PM; Wells AU
Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
13. Idiopathic pulmonary fibrosis in the era of antifibrotic therapy: Searching for new opportunities grounded in evidence.
Robalo-Cordeiro C; Campos P; Carvalho L; Borba A; Clemente S; Freitas S; Furtado S; Jesus JM; Leal C; Marques A; Melo N; Souto-Moura C; Neves S; Sousa V; Santos A; Morais A
Rev Port Pneumol (2006); 2017; 23(5):287-293. PubMed ID: 28668400
[TBL] [Abstract][Full Text] [Related]
14. COUNTERPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? No.
Brown KK
Chest; 2016 Aug; 150(2):276-8. PubMed ID: 27292046
[No Abstract] [Full Text] [Related]
15. Novel treatments for idiopathic pulmonary fibrosis.
Spagnolo P
Am J Med; 2015 May; 128(5):447-9. PubMed ID: 25613299
[No Abstract] [Full Text] [Related]
16. POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes.
King CS; Nathan SD
Chest; 2016 Aug; 150(2):273-5. PubMed ID: 27292047
[No Abstract] [Full Text] [Related]
17. Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study.
Moor CC; Mostard RLM; Grutters JC; Bresser P; Aerts JGJV; Dirksen CD; Kimman ML; Wijsenbeek MS
Respir Res; 2020 Jul; 21(1):196. PubMed ID: 32703201
[TBL] [Abstract][Full Text] [Related]
18. Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis.
Selvaggio AS; Noble PW
Annu Rev Med; 2016; 67():487-95. PubMed ID: 26565677
[TBL] [Abstract][Full Text] [Related]
19. Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group.
Sköld CM; Bendstrup E; Myllärniemi M; Gudmundsson G; Sjåheim T; Hilberg O; Altraja A; Kaarteenaho R; Ferrara G
J Intern Med; 2017 Feb; 281(2):149-166. PubMed ID: 27862475
[TBL] [Abstract][Full Text] [Related]
20. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]